$ELDN
Eledon Pharmaceuticals, Inc.

2017 Q2 Form 10-Q Financial Statement

#000119312517156191 Filed on May 03, 2017

View on sec.gov

Income Statement

Concept 2017 Q2 2017 Q1 2016 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $6.130M $910.0K $2.720M
YoY Change 66.58% -74.37% -18.56%
% of Gross Profit
Research & Development $533.0K $306.0K $1.040M
YoY Change -9.97% -96.14% -86.55%
% of Gross Profit
Depreciation & Amortization $0.00 $17.00K $20.00K
YoY Change -100.0% -67.92% -66.67%
% of Gross Profit
Operating Expenses $6.666M $1.385M $3.760M
YoY Change 615.24% -87.94% -66.03%
Operating Profit -$6.666M -$1.385M -$3.760M
YoY Change 615.24% -87.94% -66.04%
Interest Expense $20.00K
YoY Change -66.67%
% of Operating Profit
Other Income/Expense, Net $4.000K $11.00K
YoY Change -105.71%
Pretax Income -$6.660M -$1.370M -$3.740M
YoY Change -50.78% -88.01% -66.06%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$6.662M -$1.374M -$3.737M
YoY Change 564.87% -87.97% -66.08%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$28.96M -$7.611M -$26.71M
COMMON SHARES
Basic Shares Outstanding 22.64M shares 22.64M shares 22.64M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2017 Q2 2017 Q1 2016 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $22.50M $24.40M $27.40M
YoY Change -48.75% -55.06% -57.19%
Cash & Equivalents $22.50M $24.40M $1.103M
Short-Term Investments $0.00 $4.200M
Other Short-Term Assets $2.300M $1.200M $33.00K
YoY Change 0.0% -55.56% -98.97%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $24.84M $25.63M $1.150M
YoY Change -46.21% -55.02% -98.29%
LONG-TERM ASSETS
Property, Plant & Equipment $49.00K $80.00K $31.00K
YoY Change -87.78% -82.34% -93.66%
Goodwill $1.867M
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $15.00K $100.0K $15.00K
YoY Change -95.0% -66.67% -66.67%
Total Long-Term Assets $2.001M $200.0K $46.00K
YoY Change 198.21% -72.34% -94.28%
TOTAL ASSETS
Total Short-Term Assets $24.84M $25.63M $1.150M
Total Long-Term Assets $2.001M $200.0K $46.00K
Total Assets $26.84M $25.83M $1.196M
YoY Change -42.71% -55.24% -98.24%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $374.0K $276.0K $338.0K
YoY Change -79.74% -85.37% -72.02%
Accrued Expenses $1.486M $2.143M $113.0K
YoY Change -75.11% -50.06% -97.72%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.160M $2.419M $3.898M
YoY Change -59.58% -60.84% -36.74%
LONG-TERM LIABILITIES
Long-Term Debt $200.0K $0.00 $100.0K
YoY Change 0.0% -100.0% 0.0%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $245.0K $48.00K $84.00K
YoY Change 57.05% -61.9% -4.55%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.160M $2.419M $3.898M
Total Long-Term Liabilities $245.0K $48.00K $84.00K
Total Liabilities $3.405M $2.467M $3.898M
YoY Change -57.29% -60.86% -37.63%
SHAREHOLDERS EQUITY
Retained Earnings -$22.43M -$173.3M -$14.39M
YoY Change -85.66% 21.28% -89.05%
Common Stock $45.87M $196.6M $11.39M
YoY Change -76.51% 1.21% -94.11%
Preferred Stock $291.0K
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $23.44M $23.36M -$2.702M
YoY Change
Total Liabilities & Shareholders Equity $26.84M $25.83M $1.196M
YoY Change -42.71% -55.24% -98.24%

Cashflow Statement

Concept 2017 Q2 2017 Q1 2016 Q4
OPERATING ACTIVITIES
Net Income -$6.662M -$1.374M -$3.737M
YoY Change 564.87% -87.97% -66.08%
Depreciation, Depletion And Amortization $0.00 $17.00K $20.00K
YoY Change -100.0% -67.92% -66.67%
Cash From Operating Activities -$5.760M -$3.150M -$7.310M
YoY Change -44.08% -67.66% -17.68%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00
YoY Change -100.0% -100.0%
Acquisitions
YoY Change
Other Investing Activities $18.93M $4.330M $11.90M
YoY Change 132.27% -12000.0%
Cash From Investing Activities $18.93M $4.330M $11.90M
YoY Change 132.27% -21750.0% -3818.75%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 7.120M 0.000 0.000
YoY Change -100.0% -100.0%
NET CHANGE
Cash From Operating Activities -5.760M -3.150M -7.310M
Cash From Investing Activities 18.93M 4.330M 11.90M
Cash From Financing Activities 7.120M 0.000 0.000
Net Change In Cash 20.29M -482.0K 4.590M
YoY Change -1043.72% -95.04% -150.11%
FREE CASH FLOW
Cash From Operating Activities -$5.760M -$3.150M -$7.310M
Capital Expenditures $0.00 $0.00
Free Cash Flow -$3.150M -$7.310M
YoY Change -67.72% -15.59%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2016Q4 tkai Termination Fee Payable
TerminationFeePayable
1000000
CY2017Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
22641651 shares
CY2016Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14303000
CY2017Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
186000
CY2017Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2017Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
22641651 shares
CY2017Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
22641651 shares
CY2017Q1 us-gaap Assets
Assets
25831000
CY2017Q1 us-gaap Assets Current
AssetsCurrent
25631000
CY2017Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2017Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
196604000
CY2017Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
24400000
CY2017Q1 us-gaap Common Stock Value
CommonStockValue
23000
CY2017Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
276000
CY2017Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1105000
CY2017Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2143000
CY2017Q1 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
1118000
CY2017Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2017Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2017Q1 us-gaap Marketable Securities
MarketableSecurities
0
CY2017Q1 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
48000
CY2017Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2017Q1 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0
CY2017Q1 us-gaap Liabilities
Liabilities
2467000
CY2017Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
25831000
CY2017Q1 us-gaap Liabilities Current
LiabilitiesCurrent
2419000
CY2017Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
229000
CY2017Q1 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
629000
CY2017Q1 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
22943000
CY2017Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2017Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
80000
CY2017Q1 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
489000
CY2017Q1 us-gaap Stockholders Equity
StockholdersEquity
23364000
CY2017Q1 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2016Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
84000
CY2016Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2016Q4 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0
CY2016Q4 us-gaap Liabilities
Liabilities
2903000
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
29761000
CY2017Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-173263000
CY2017Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1231000
CY2017Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2017Q1 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
120000
CY2017Q1 tkai Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
623000
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
24023000
CY2016Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
394000
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
22641651 shares
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
22641651 shares
CY2016Q4 us-gaap Assets
Assets
29761000
CY2016Q4 us-gaap Assets Current
AssetsCurrent
29543000
CY2016Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0
CY2016Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1000
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2016Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
4175000
CY2016Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
196233000
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
23223000
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
23000
CY2016Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
4176000
CY2016Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
430000
CY2016Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
871000
CY2016Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1000
CY2016Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
65643000
CY2016Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2389000
CY2016Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2819000
CY2016Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
217000
CY2016Q4 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
21923000
CY2016Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2016Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
98000
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
26858000
CY2016Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-169397000
CY2016Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1995000
CY2016Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2016Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
150000
CY2016Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
120000
CY2016Q4 tkai Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
907000
CY2016Q4 tkai Advisory Fees Payable
AdvisoryFeesPayable
500000
CY2017Q1 tkai Minimum Stock Price For Continued Listing
MinimumStockPriceForContinuedListing
1.00
CY2017Q1 tkai Number Of Consecutive Trading Periods For Continued Listing
NumberOfConsecutiveTradingPeriodsForContinuedListing
P10D
CY2017Q1 tkai Number Of Patients
NumberOfPatients
10 Patient
CY2017Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-1000
CY2017Q1 dei Entity Registrant Name
EntityRegistrantName
TOKAI PHARMACEUTICALS INC
CY2017Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1855741 shares
CY2017Q1 dei Document Type
DocumentType
10-Q
CY2017Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001404281
CY2017Q1 dei Document Period End Date
DocumentPeriodEndDate
2017-03-31
CY2017Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
1177000
CY2017Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.17
CY2017Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
371000
CY2017Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2017
CY2017Q1 dei Amendment Flag
AmendmentFlag
false
CY2017Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2017Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3586000
CY2017Q1 us-gaap Depreciation
Depreciation
17000
CY2017Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2017Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3865000
CY2017Q1 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2017Q1 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
19000
CY2017Q1 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
175000
CY2017Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-246000
CY2017Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-36000
CY2017Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
1000
CY2017Q1 us-gaap Operating Expenses
OperatingExpenses
3892000
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-3866000
CY2017Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
4325000
CY2017Q1 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
1000
CY2017Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-154000
CY2017Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-764000
CY2017Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-3892000
CY2017Q1 us-gaap Interest And Other Income
InterestAndOtherIncome
26000
CY2017Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2017Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-3148000
CY2017Q1 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
-150000
CY2017Q1 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> <b><i>Use of Estimates</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The preparation of financial statements in conformity with GAAP requires management to make estimates, assumptions and judgments that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of expenses during the reporting periods. Significant estimates, assumptions and judgments reflected in these financial statements include, but are not limited to, the accrual of research and development expenses and the valuation of stock-based awards. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Actual results could differ from the Company&#x2019;s estimates.</p> </div>
CY2017Q1 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
0
CY2017Q1 dei Trading Symbol
TradingSymbol
TKAI
CY2017Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
306000
CY2017Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
4175000
CY2017Q1 us-gaap Tangible Asset Impairment Charges
TangibleAssetImpairmentCharges
1000
CY2017Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
22641651 shares
CY2017Q1 tkai Earliest Year Open For Tax Examination
EarliestYearOpenForTaxExamination
2013
CY2017Q1 tkai Increase Decrease In Deferred Tax Assets
IncreaseDecreaseInDeferredTaxAssets
1000000
CY2017Q1 tkai Number Of Milestones Achieved
NumberOfMilestonesAchieved
0 Milestone
CY2016Q1 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
50000
CY2016Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
678000
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
-11426000
CY2016Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-17000
CY2017Q1 tkai Strategic Advisor Fees
StrategicAdvisorFees
500000
CY2017Q1 tkai Continued Listing Requirements
ContinuedListingRequirements
On March 8, 2017, the Company received a deficiency letter from the Listing Qualifications Department of the NASDAQ Stock Market notifying the Company that, for the last 30 consecutive business days prior to the date of the letter, the bid price for its common stock had closed below the minimum $1.00 per share requirement for continued inclusion on the NASDAQ Global Market. The Company has been provided an initial period of 180 calendar days, or until September 4, 2017, to regain compliance with the listing requirements. If, at any time before September 4, 2017, the bid price for the Company’s common stock closes at $1.00 or more for a minimum of 10 consecutive business days it may be eligible to regain compliance with the minimum bid requirement. Under certain circumstances, NASDAQ could require that the minimum bid price exceed $1.00 for more than ten consecutive days before determining that the Company complies with NASDAQ’s continued listing standards.
CY2016Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-37000
CY2016Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3069443 shares
CY2016Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-9720000
CY2016Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.51
CY2016Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1022000
CY2016Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3549000
CY2016Q1 us-gaap Depreciation
Depreciation
53000
CY2016Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11376000
CY2016Q1 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
45000
CY2016Q1 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
174000
CY2016Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-663000
CY2016Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
38000
CY2016Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
50000
CY2016Q1 us-gaap Operating Expenses
OperatingExpenses
11480000
CY2016Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-521000
CY2016Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-11480000
CY2016Q1 us-gaap Interest And Other Income
InterestAndOtherIncome
54000
CY2016Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
37000
CY2016Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2016Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-9740000
CY2016Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
17000
CY2016Q1 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
0
CY2016Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7931000
CY2016Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
37000
CY2016Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
22625009 shares
CY2016Q1 tkai Number Of Milestones Achieved
NumberOfMilestonesAchieved
0 Milestone
CY2016Q3 us-gaap Restructuring And Related Cost Number Of Positions Eliminated Period Percent
RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
0.60 pure

Files In Submission

Name View Source Status
0001193125-17-156191-index-headers.html Edgar Link pending
0001193125-17-156191-index.html Edgar Link pending
0001193125-17-156191.txt Edgar Link pending
0001193125-17-156191-xbrl.zip Edgar Link pending
d265983d10q.htm Edgar Link pending
d265983dex311.htm Edgar Link pending
d265983dex312.htm Edgar Link pending
d265983dex321.htm Edgar Link pending
d265983dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tkai-20170331.xml Edgar Link completed
tkai-20170331.xsd Edgar Link pending
tkai-20170331_cal.xml Edgar Link unprocessable
tkai-20170331_def.xml Edgar Link unprocessable
tkai-20170331_lab.xml Edgar Link unprocessable
tkai-20170331_pre.xml Edgar Link unprocessable